Allergic Conjunctivitis Market Research, 2031
The global allergic conjunctivitis market was valued at $1,937.99 million in 2021, and is estimated to reach $2,954.2 million by 2031, growing at a CAGR of 4.28%from 2022 to 2031. Allergic conjunctivitis, is an eye irritation, which can be caused by an allergic reaction to items such as pollen or mold spores. A membrane called the conjunctiva covers the surface of the eyeball and the interior of the eyelids. Conjunctival irritation from allergens is possible, especially during the hay fever season. Allergy-related conjunctivitis is highly common. It is an individual body's response to compounds that it perceives as potentially hazardous. Conjunctivitis caused by allergens is more common in those with allergies. According to the Asthma and Allergy Foundation of America, allergies run in families and impact 30% of adults and 40% of children. Common signs of allergic conjunctivitis include red, watery, burning, and itchy eyes.
Increase in patient population of allergic conjunctivitis worldwide and escalating demand for healthcare services is expected to majorly drive the market growth. In addition, many key market players are focusing on R&D activities to develop drugs for allergic conjunctivitis as patient population is increasing, which also drives the allergic conjunctivitis market growth.
Furthermore, rise in exposure to pollutants and chemicals causes allergic conjunctivitis and is also expected to propel the allergic conjunctivitis market forecast. However, adverse reaction of allergic conjunctivitis medications can impede the growth of the market. Conversely, increase in awareness about the disease creates allergic conjunctivitis market opportunity for the key players to invest.
Impact of COVID-19
The COVID-19 outbreak is anticipated to have a negative impact on the allergic conjunctivitis industry. A huge number of clinics and hospitals across the globe were restructured to increase hospital capacity for patients diagnosed with COVID-19. Non-essential procedures took a potential backlog, owing to rapidly rising COVID-19 cases. The lockdown led to disruption of manufacturing and transportation of healthcare essentials. Furthermore, other factors responsible for the impact on the market include limited availability of medical care, shortage of healthcare staff, and rise in burden of COVID-19 related hospitalization.
The COVID-19 outbreak is anticipated to have a negative impact on the growth of the global allergic conjunctivitis market. The main cause of negative impact on the market is the interruptions experienced by patients for getting treatment for allergic conjunctivitis in the healthcare facilities due to risk of COVID-19 infection.
Allergic Conjunctivitis Market Segmentation
The global allergic conjunctivitis market is segmented on the basis of drug class, disease type, distribution channel, and region. On the basis of drug type, the market is categorized into antihistamines & mast cell, corticosteroids, and others. By disease type, it is divided into seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC). The seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC) are further sub-segmented each by age group into pediatric and adult. By distribution channel, it is segmented into hospital pharmacies, drug store & retail pharmacies and online providers. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).
Segment Review
By drug class, the allergic conjunctivitis market size is segmented into antihistamines & mast cell stabilizers, corticosteroids, and others. The antihistamines & mast cell stabilizers segment generated maximum revenue in 2021, accounting $1171.22 million and is also expected to witness highest CAGR of 4.81% during the forecast period, owing to new product launches by various key market players.
Depending on disease type, the allergic conjunctivitis market size is divided into seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC) The seasonal allergic conjunctivitis (SAC) segment dominated the market in 2021, with $1264.98million and is expected to witness highest CAGR of 4.66% during the forecast period, owing to prevalence of seasonal allergic conjunctivitis.
Depending on distribution channel, the market is divided into hospital pharmacies, drug store & retail pharmacies and online providers. The drug stores & retail pharmacies segment dominated the market in 2021, with $1174.69million owing to present in commercial areas of a community. The online providers segment is expected to witness highest CAGR of 3.85% during the forecast period, owing to popular medium for purchase of medicines.
North America accounted for a majority of the global allergic conjunctivitis market share in 2021, and is anticipated to remain dominant during the forecast period. This is attributed to technological advancements in allergic conjunctivitis techniques, integration of advanced drugs in allergic conjunctivitis devices, and presence of key and robust hospital infrastructure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in patient population, development of healthcare infrastructure and increase in investments projects in the region.
The major players profiled in the report are AbbVie Inc., Ajanta Pharma Limited, Akron Operating Company LLC, Alembic Pharmaceuticals Ltd, Bausch Health Companies Inc., Cipla, Inc., Grevis Pharmaceutical Private Limited, Indoco Remedies Ltd., Jabs Biotech Pvt. Ltd., JAWA Pharmaceuticals Pvt. Ltd, Johnson & Johnson Services Inc., Novartis AG, Novartis AG, Santen Pharmaceuticals Co. Ltd., Spectra Vision Care Pvt. Ltd., Sun Pharmaceuticals Industries Ltd., and Teva Pharmaceutical Industries Ltd.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the allergic conjunctivitis market analysis from 2021 to 2031 to identify the prevailing allergic conjunctivitis market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the allergic conjunctivitis market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global allergic conjunctivitis market trends, key players, market segments, application areas, and market growth strategies.
Allergic Conjunctivitis Market Report Highlights
| Aspects | Details |
 By Drug Class |
|
 By Disease Type |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Sun Pharmaceuticals Industries Ltd, Bausch Health Companies Inc., Grevis Pharmaceutical Private Limited, Johnson and Johnson, AbbVie Inc., Indoco Remedies Ltd., Akron Operating Company LLC, Alembic Pharmaceuticals Ltd., Jabs Biotech Pvt. Ltd., Cipla Ltd, Spectra Vision Care Pvt. Ltd., Ocular Therapeutics, Inc., Ajanta Pharma Limited, Novartis AG, Teva Pharmaceutical Industries Ltd., JAWA Pharmaceuticals Pvt. Ltd., Santen Pharmaceuticals Co. Ltd. |
Analyst Review
This section provides opinions of top level CXOs in the global allergic conjunctivitis market. According to the insights of CXOs of leading companies in the market, development of advanced and reliable allergic conjunctivitis drugs, increase in patient population and better healthcare services is also expected to propel the allergic conjunctivitis market.
The allergic conjunctivitis industry holds high potential, owing to innovative concepts and multidisciplinary expertise demand for new drug development with less side effects in the creation of allergic conjunctivitis drugs. The market gains interest of healthcare companies, owing to its unmet demands in developing economies such as India and China where the population is growing rapidly along with allergies load.
North America is expected to witness highest growth, in terms of revenue, owing to increase in cases of conjunctivitis, robust healthcare infrastructure, presence of key players, and rise in healthcare expenditure. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in patient population, unmet medical demands, initiatives by government & non-governmental organizations (NGOs) to promote awareness regarding allergic conjunctivitis, and increase in public–private investments in the healthcare sector.
North America is the largest regional market for allergic conjunctivitis.
Increase in patient population of allergic conjunctivitis worldwide and escalating demand for healthcare services are the upcoming trends of allergic conjunctivitis market.
The global allergic conjunctivitis market was valued at $1,937.99 million in 2021, and is estimated to reach $2,954.2 million by 2031, growing at a CAGR of 4.28%from 2022 to 2031.
Antihistamines & mast cell stabilizers is the leading drug class of allergic conjunctivitis market.
2021 is considered the base year for the allergic conjunctivitis market.
The analysis period of the allergic conjunctivitis market is from 2021 to 2031.
AbbVie Inc., Johnson & Johnson Services Inc., Novartis AG, Alembic Pharmaceuticals Ltd, Bausch Health Companies Inc., Cipla, Inc., Sun Pharmaceuticals Industries Ltd., and Teva Pharmaceutical Industries Ltd are the top companies to hold the market share in allergic conjunctivitis market.
Loading Table Of Content...
